Live feed19:30:00·5mPRReleasevia QuantisnowNew Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramByQuantisnow·Wall Street's wire, on your screen.CGEM· Cullinan Therapeutics Inc.Health Care
